Recombinant MFG-E8 - TheraSource

Drug Profile

Recombinant MFG-E8 - TheraSource

Alternative Names: Recombinant human MFG-E8; Recombinant lactadherin; Recombinant MFG-E8; rhMFG-E8

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraSource
  • Class Anti-inflammatories; Proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute kidney injury; Haemorrhagic shock; Inflammatory bowel diseases

Highest Development Phases

  • Preclinical Acute kidney injury; Haemorrhagic shock; Inflammatory bowel diseases

Most Recent Events

  • 03 Aug 2016 Preclinical development in Acute kidney injury is ongoing in USA
  • 03 Aug 2016 Recombinant MFG-E8 - TheraSource is available for licensing as of 04 Aug 2016. http://therasourceinc.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top